[
  {
    "title": "Incyte First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag",
    "published": 1714833361,
    "day_prices": {},
    "sentiment": 0.8663451075553894
  },
  {
    "title": "Incyte to Present at Upcoming Investor Conference",
    "published": 1714651200,
    "day_prices": {
      "2024-05-02T13:30:00+00:00": 53.02000045776367,
      "2024-05-02T14:30:00+00:00": 52.720001220703125,
      "2024-05-02T15:30:00+00:00": 52.95000076293945,
      "2024-05-02T16:30:00+00:00": 53.150001525878906,
      "2024-05-02T17:30:00+00:00": 53.290000915527344,
      "2024-05-02T18:30:00+00:00": 53.040000915527344,
      "2024-05-02T19:30:00+00:00": 53.060001373291016
    },
    "sentiment": 0.9380808472633362
  },
  {
    "title": "Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript",
    "published": 1714576377,
    "day_prices": {
      "2024-05-01T13:30:00+00:00": 51.9900016784668,
      "2024-05-01T14:30:00+00:00": 53.89500045776367,
      "2024-05-01T15:30:00+00:00": 53.209999084472656,
      "2024-05-01T16:30:00+00:00": 52.45000076293945,
      "2024-05-01T17:30:00+00:00": 52.25,
      "2024-05-01T18:30:00+00:00": 52.45000076293945,
      "2024-05-01T19:30:00+00:00": 53.279998779296875
    },
    "sentiment": 0.9347323775291443
  },
  {
    "title": "Incyte price target lowered by $8 at TD Cowen, here's why",
    "published": 1714545420,
    "day_prices": {
      "2024-05-01T13:30:00+00:00": 51.9900016784668,
      "2024-05-01T14:30:00+00:00": 53.89500045776367,
      "2024-05-01T15:30:00+00:00": 53.209999084472656,
      "2024-05-01T16:30:00+00:00": 52.45000076293945,
      "2024-05-01T17:30:00+00:00": 52.25,
      "2024-05-01T18:30:00+00:00": 52.45000076293945,
      "2024-05-01T19:30:00+00:00": 53.279998779296875
    },
    "sentiment": 0.7964009046554565
  },
  {
    "title": "RBC Capital Reaffirms Their Hold Rating on Incyte (INCY)",
    "published": 1714541940,
    "day_prices": {
      "2024-05-01T13:30:00+00:00": 51.9900016784668,
      "2024-05-01T14:30:00+00:00": 53.89500045776367,
      "2024-05-01T15:30:00+00:00": 53.209999084472656,
      "2024-05-01T16:30:00+00:00": 52.45000076293945,
      "2024-05-01T17:30:00+00:00": 52.25,
      "2024-05-01T18:30:00+00:00": 52.45000076293945,
      "2024-05-01T19:30:00+00:00": 53.279998779296875
    },
    "sentiment": 0.8489096760749817
  },
  {
    "title": "Biotech Alert: Searches spiking for these stocks today",
    "published": 1715766060,
    "day_prices": {
      "2024-05-15T13:30:00+00:00": 57.43000030517578,
      "2024-05-15T14:30:00+00:00": 57.060001373291016,
      "2024-05-15T15:30:00+00:00": 56.994998931884766,
      "2024-05-15T16:30:00+00:00": 57.09000015258789,
      "2024-05-15T17:30:00+00:00": 57.334999084472656,
      "2024-05-15T18:30:00+00:00": 57.209999084472656,
      "2024-05-15T19:30:00+00:00": 57.18000030517578
    },
    "sentiment": 0.7777091860771179
  },
  {
    "title": "Incyte Launches $1.67 Billion Share Repurchase 'Dutch Auction' Tender Offer; to Buy Back $328 Million of Baker Entities' Shares",
    "published": 1715603069,
    "day_prices": {
      "2024-05-13T13:30:00+00:00": 57.11000061035156,
      "2024-05-13T14:30:00+00:00": 57.25,
      "2024-05-13T15:30:00+00:00": 57.25,
      "2024-05-13T16:30:00+00:00": 57.18000030517578,
      "2024-05-13T17:30:00+00:00": 57.060001373291016,
      "2024-05-13T18:30:00+00:00": 57.275001525878906,
      "2024-05-13T19:30:00+00:00": 57.38999938964844
    },
    "sentiment": 0.8528287410736084
  },
  {
    "title": "Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock",
    "published": 1715598000,
    "day_prices": {
      "2024-05-13T13:30:00+00:00": 57.11000061035156,
      "2024-05-13T14:30:00+00:00": 57.25,
      "2024-05-13T15:30:00+00:00": 57.25,
      "2024-05-13T16:30:00+00:00": 57.18000030517578,
      "2024-05-13T17:30:00+00:00": 57.060001373291016,
      "2024-05-13T18:30:00+00:00": 57.275001525878906,
      "2024-05-13T19:30:00+00:00": 57.38999938964844
    },
    "sentiment": 0.8140183687210083
  },
  {
    "title": "Unveiling Incyte (INCY)'s Value: Is It Really Priced Right? A Comprehensive Guide",
    "published": 1715592720,
    "day_prices": {
      "2024-05-13T13:30:00+00:00": 57.11000061035156,
      "2024-05-13T14:30:00+00:00": 57.25,
      "2024-05-13T15:30:00+00:00": 57.25,
      "2024-05-13T16:30:00+00:00": 57.18000030517578,
      "2024-05-13T17:30:00+00:00": 57.060001373291016,
      "2024-05-13T18:30:00+00:00": 57.275001525878906,
      "2024-05-13T19:30:00+00:00": 57.38999938964844
    },
    "sentiment": 0.8820518851280212
  },
  {
    "title": "Early notable gainers among liquid option names on May 13th",
    "published": 1715590500,
    "day_prices": {
      "2024-05-13T13:30:00+00:00": 57.11000061035156,
      "2024-05-13T14:30:00+00:00": 57.25,
      "2024-05-13T15:30:00+00:00": 57.25,
      "2024-05-13T16:30:00+00:00": 57.18000030517578,
      "2024-05-13T17:30:00+00:00": 57.060001373291016,
      "2024-05-13T18:30:00+00:00": 57.275001525878906,
      "2024-05-13T19:30:00+00:00": 57.38999938964844
    },
    "sentiment": 0.8949373960494995
  },
  {
    "title": "Incyte jumps 6%, intends to buy back $2B stock",
    "published": 1715584200,
    "day_prices": {
      "2024-05-13T13:30:00+00:00": 57.11000061035156,
      "2024-05-13T14:30:00+00:00": 57.25,
      "2024-05-13T15:30:00+00:00": 57.25,
      "2024-05-13T16:30:00+00:00": 57.18000030517578,
      "2024-05-13T17:30:00+00:00": 57.060001373291016,
      "2024-05-13T18:30:00+00:00": 57.275001525878906,
      "2024-05-13T19:30:00+00:00": 57.38999938964844
    },
    "sentiment": 0.7418080568313599
  },
  {
    "title": "Incyte announces intention to repurchase up to $2B common stock",
    "published": 1715581620,
    "day_prices": {
      "2024-05-13T13:30:00+00:00": 57.11000061035156,
      "2024-05-13T14:30:00+00:00": 57.25,
      "2024-05-13T15:30:00+00:00": 57.25,
      "2024-05-13T16:30:00+00:00": 57.18000030517578,
      "2024-05-13T17:30:00+00:00": 57.060001373291016,
      "2024-05-13T18:30:00+00:00": 57.275001525878906,
      "2024-05-13T19:30:00+00:00": 57.38999938964844
    },
    "sentiment": 0.86984783411026
  },
  {
    "title": "Stock market today: Wall Street barely budges as S&P 500 remains just shy of its record",
    "published": 1715561700,
    "day_prices": {
      "2024-05-13T13:30:00+00:00": 57.11000061035156,
      "2024-05-13T14:30:00+00:00": 57.25,
      "2024-05-13T15:30:00+00:00": 57.25,
      "2024-05-13T16:30:00+00:00": 57.18000030517578,
      "2024-05-13T17:30:00+00:00": 57.060001373291016,
      "2024-05-13T18:30:00+00:00": 57.275001525878906,
      "2024-05-13T19:30:00+00:00": 57.38999938964844
    },
    "sentiment": 0.9564318060874939
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)",
    "published": 1715322660,
    "day_prices": {
      "2024-05-10T13:30:00+00:00": 53.38999938964844,
      "2024-05-10T14:30:00+00:00": 53.470001220703125,
      "2024-05-10T15:30:00+00:00": 53.25,
      "2024-05-10T16:30:00+00:00": 53.165000915527344,
      "2024-05-10T17:30:00+00:00": 53.084999084472656,
      "2024-05-10T18:30:00+00:00": 53.0,
      "2024-05-10T19:30:00+00:00": 53.209999084472656
    },
    "sentiment": 0.8984269499778748
  },
  {
    "title": "9 Analysts Have This To Say About Incyte",
    "published": 1716447840,
    "day_prices": {
      "2024-05-23T13:30:00+00:00": 57.869998931884766,
      "2024-05-23T14:30:00+00:00": 57.84000015258789,
      "2024-05-23T15:30:00+00:00": 57.849998474121094,
      "2024-05-23T16:30:00+00:00": 58.029998779296875,
      "2024-05-23T17:30:00+00:00": 58.040000915527344,
      "2024-05-23T18:30:00+00:00": 57.709999084472656,
      "2024-05-23T19:30:00+00:00": 57.70000076293945
    },
    "sentiment": 0.9266036748886108
  },
  {
    "title": "Incyte initiated with neutral view at Deutsche Bank, here's why",
    "published": 1716443700,
    "day_prices": {
      "2024-05-23T13:30:00+00:00": 57.869998931884766,
      "2024-05-23T14:30:00+00:00": 57.84000015258789,
      "2024-05-23T15:30:00+00:00": 57.849998474121094,
      "2024-05-23T16:30:00+00:00": 58.029998779296875,
      "2024-05-23T17:30:00+00:00": 58.040000915527344,
      "2024-05-23T18:30:00+00:00": 57.709999084472656,
      "2024-05-23T19:30:00+00:00": 57.70000076293945
    },
    "sentiment": 0.92005854845047
  },
  {
    "title": "Incyte\u2019s Share Buyback Program: A Buy Rating and Fundamental Value Increase",
    "published": 1715828880,
    "day_prices": {
      "2024-05-16T13:30:00+00:00": 56.86000061035156,
      "2024-05-16T14:30:00+00:00": 56.939998626708984,
      "2024-05-16T15:30:00+00:00": 56.66999816894531,
      "2024-05-16T16:30:00+00:00": 56.5,
      "2024-05-16T17:30:00+00:00": 56.81999969482422,
      "2024-05-16T18:30:00+00:00": 56.869998931884766,
      "2024-05-16T19:30:00+00:00": 56.790000915527344
    },
    "sentiment": 0.8877170085906982
  },
  {
    "title": "Incyte Completes Acquisition of Escient Pharmaceuticals",
    "published": 1717099500,
    "day_prices": {
      "2024-05-30T13:30:00+00:00": 57.04999923706055,
      "2024-05-30T14:30:00+00:00": 57.11000061035156,
      "2024-05-30T15:30:00+00:00": 57.2599983215332,
      "2024-05-30T16:30:00+00:00": 57.42530059814453,
      "2024-05-30T17:30:00+00:00": 57.5,
      "2024-05-30T18:30:00+00:00": 57.33000183105469,
      "2024-05-30T19:30:00+00:00": 57.439998626708984
    },
    "sentiment": 0.8956124186515808
  },
  {
    "title": "Analyst Expectations For Incyte's Future",
    "published": 1718701320,
    "day_prices": {
      "2024-06-18T13:30:00+00:00": 62.650001525878906,
      "2024-06-18T14:30:00+00:00": 62.880001068115234,
      "2024-06-18T15:30:00+00:00": 62.22999954223633,
      "2024-06-18T16:30:00+00:00": 61.790000915527344,
      "2024-06-18T17:30:00+00:00": 61.25,
      "2024-06-18T18:30:00+00:00": 61.63999938964844,
      "2024-06-18T19:30:00+00:00": 61.45000076293945
    },
    "sentiment": 0.7691176533699036
  },
  {
    "title": "Incyte: The Worst Has Been Avoided",
    "published": 1718525547,
    "day_prices": {},
    "sentiment": 0.7662290334701538
  },
  {
    "title": "Incyte Announces Final Results of Tender Offer",
    "published": 1718280000,
    "day_prices": {
      "2024-06-13T13:30:00+00:00": 59.970001220703125,
      "2024-06-13T14:30:00+00:00": 60.650001525878906,
      "2024-06-13T15:30:00+00:00": 60.689998626708984,
      "2024-06-13T16:30:00+00:00": 60.900001525878906,
      "2024-06-13T17:30:00+00:00": 62.29999923706055,
      "2024-06-13T18:30:00+00:00": 62.66999816894531,
      "2024-06-13T19:30:00+00:00": 62.33000183105469
    },
    "sentiment": 0.9188425540924072
  },
  {
    "title": "Analysts Conflicted on These Healthcare Names: Incyte (INCY) and Lisata Therapeutics (LSTA)",
    "published": 1718276460,
    "day_prices": {
      "2024-06-13T13:30:00+00:00": 59.970001220703125,
      "2024-06-13T14:30:00+00:00": 60.650001525878906,
      "2024-06-13T15:30:00+00:00": 60.689998626708984,
      "2024-06-13T16:30:00+00:00": 60.900001525878906,
      "2024-06-13T17:30:00+00:00": 62.29999923706055,
      "2024-06-13T18:30:00+00:00": 62.66999816894531,
      "2024-06-13T19:30:00+00:00": 62.33000183105469
    },
    "sentiment": 0.66330885887146
  },
  {
    "title": "Incyte call volume above normal and directionally bullish",
    "published": 1718244300,
    "day_prices": {
      "2024-06-13T13:30:00+00:00": 59.970001220703125,
      "2024-06-13T14:30:00+00:00": 60.650001525878906,
      "2024-06-13T15:30:00+00:00": 60.689998626708984,
      "2024-06-13T16:30:00+00:00": 60.900001525878906,
      "2024-06-13T17:30:00+00:00": 62.29999923706055,
      "2024-06-13T18:30:00+00:00": 62.66999816894531,
      "2024-06-13T19:30:00+00:00": 62.33000183105469
    },
    "sentiment": 0.792332649230957
  },
  {
    "title": "Incyte Announces Preliminary Results of Tender Offer",
    "published": 1718107200,
    "day_prices": {
      "2024-06-11T13:30:00+00:00": 59.40999984741211,
      "2024-06-11T14:30:00+00:00": 58.25,
      "2024-06-11T15:30:00+00:00": 58.369998931884766,
      "2024-06-11T16:30:00+00:00": 58.90999984741211,
      "2024-06-11T17:30:00+00:00": 58.81999969482422,
      "2024-06-11T18:30:00+00:00": 59.209999084472656,
      "2024-06-11T19:30:00+00:00": 59.29999923706055
    },
    "sentiment": 0.9226129055023193
  },
  {
    "title": "We Think Shareholders Are Less Likely To Approve A Pay Rise For Incyte Corporation's (NASDAQ:INCY) CEO For Now",
    "published": 1717669017,
    "day_prices": {
      "2024-06-06T13:30:00+00:00": 58.90999984741211,
      "2024-06-06T14:30:00+00:00": 59.099998474121094,
      "2024-06-06T15:30:00+00:00": 58.86000061035156,
      "2024-06-06T16:30:00+00:00": 58.709999084472656,
      "2024-06-06T17:30:00+00:00": 58.5,
      "2024-06-06T18:30:00+00:00": 58.20000076293945,
      "2024-06-06T19:30:00+00:00": 58.279998779296875
    },
    "sentiment": 0.6389425992965698
  },
  {
    "title": "TD Cowen Sticks to Their Buy Rating for Incyte (INCY)",
    "published": 1717482960,
    "day_prices": {
      "2024-06-04T13:30:00+00:00": 58.66999816894531,
      "2024-06-04T14:30:00+00:00": 59.08000183105469,
      "2024-06-04T15:30:00+00:00": 58.92499923706055,
      "2024-06-04T16:30:00+00:00": 59.130001068115234,
      "2024-06-04T17:30:00+00:00": 59.07500076293945,
      "2024-06-04T18:30:00+00:00": 59.040000915527344,
      "2024-06-04T19:30:00+00:00": 58.810001373291016
    },
    "sentiment": 0.8936766982078552
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Tilray (TLRY), Day One Biopharmaceuticals (DAWN) and Incyte (INCY)",
    "published": 1722410160,
    "day_prices": {
      "2024-07-31T13:30:00+00:00": 67.77999877929688,
      "2024-07-31T14:30:00+00:00": 65.96499633789062,
      "2024-07-31T15:30:00+00:00": 65.81999969482422,
      "2024-07-31T16:30:00+00:00": 65.72000122070312,
      "2024-07-31T17:30:00+00:00": 65.83999633789062,
      "2024-07-31T18:30:00+00:00": 65.69999694824219,
      "2024-07-31T19:30:00+00:00": 65.41000366210938
    },
    "sentiment": 0.924379825592041
  },
  {
    "title": "Oppenheimer Remains a Buy on Incyte (INCY)",
    "published": 1722409740,
    "day_prices": {
      "2024-07-31T13:30:00+00:00": 67.77999877929688,
      "2024-07-31T14:30:00+00:00": 65.96499633789062,
      "2024-07-31T15:30:00+00:00": 65.81999969482422,
      "2024-07-31T16:30:00+00:00": 65.72000122070312,
      "2024-07-31T17:30:00+00:00": 65.83999633789062,
      "2024-07-31T18:30:00+00:00": 65.69999694824219,
      "2024-07-31T19:30:00+00:00": 65.41000366210938
    },
    "sentiment": 0.9365195631980896
  },
  {
    "title": "Incyte price target raised by $8 at Citi, here's why",
    "published": 1722405360,
    "day_prices": {
      "2024-07-31T13:30:00+00:00": 67.77999877929688,
      "2024-07-31T14:30:00+00:00": 65.96499633789062,
      "2024-07-31T15:30:00+00:00": 65.81999969482422,
      "2024-07-31T16:30:00+00:00": 65.72000122070312,
      "2024-07-31T17:30:00+00:00": 65.83999633789062,
      "2024-07-31T18:30:00+00:00": 65.69999694824219,
      "2024-07-31T19:30:00+00:00": 65.41000366210938
    },
    "sentiment": 0.7509812712669373
  },
  {
    "title": "Incyte (INCY) Gets a Buy from Piper Sandler",
    "published": 1722405060,
    "day_prices": {
      "2024-07-31T13:30:00+00:00": 67.77999877929688,
      "2024-07-31T14:30:00+00:00": 65.96499633789062,
      "2024-07-31T15:30:00+00:00": 65.81999969482422,
      "2024-07-31T16:30:00+00:00": 65.72000122070312,
      "2024-07-31T17:30:00+00:00": 65.83999633789062,
      "2024-07-31T18:30:00+00:00": 65.69999694824219,
      "2024-07-31T19:30:00+00:00": 65.41000366210938
    },
    "sentiment": 0.49828097224235535
  },
  {
    "title": "Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Genmab (GMAB) and Penumbra (PEN)",
    "published": 1722403980,
    "day_prices": {
      "2024-07-31T13:30:00+00:00": 67.77999877929688,
      "2024-07-31T14:30:00+00:00": 65.96499633789062,
      "2024-07-31T15:30:00+00:00": 65.81999969482422,
      "2024-07-31T16:30:00+00:00": 65.72000122070312,
      "2024-07-31T17:30:00+00:00": 65.83999633789062,
      "2024-07-31T18:30:00+00:00": 65.69999694824219,
      "2024-07-31T19:30:00+00:00": 65.41000366210938
    },
    "sentiment": 0.756259560585022
  },
  {
    "title": "Incyte Corp (INCY) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...",
    "published": 1722387720,
    "day_prices": {
      "2024-07-31T13:30:00+00:00": 67.77999877929688,
      "2024-07-31T14:30:00+00:00": 65.96499633789062,
      "2024-07-31T15:30:00+00:00": 65.81999969482422,
      "2024-07-31T16:30:00+00:00": 65.72000122070312,
      "2024-07-31T17:30:00+00:00": 65.83999633789062,
      "2024-07-31T18:30:00+00:00": 65.69999694824219,
      "2024-07-31T19:30:00+00:00": 65.41000366210938
    },
    "sentiment": 0.9543542861938477
  },
  {
    "title": "Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top",
    "published": 1722348420,
    "day_prices": {
      "2024-07-30T13:30:00+00:00": 69.33000183105469,
      "2024-07-30T14:30:00+00:00": 66.2300033569336,
      "2024-07-30T15:30:00+00:00": 66.20999908447266,
      "2024-07-30T16:30:00+00:00": 65.63999938964844,
      "2024-07-30T17:30:00+00:00": 65.8499984741211,
      "2024-07-30T18:30:00+00:00": 66.98999786376953,
      "2024-07-30T19:30:00+00:00": 66.93499755859375
    },
    "sentiment": 0.7218948006629944
  },
  {
    "title": "Incyte drops 5 clinical drug candidates following a strategic review",
    "published": 1722342420,
    "day_prices": {
      "2024-07-30T13:30:00+00:00": 69.33000183105469,
      "2024-07-30T14:30:00+00:00": 66.2300033569336,
      "2024-07-30T15:30:00+00:00": 66.20999908447266,
      "2024-07-30T16:30:00+00:00": 65.63999938964844,
      "2024-07-30T17:30:00+00:00": 65.8499984741211,
      "2024-07-30T18:30:00+00:00": 66.98999786376953,
      "2024-07-30T19:30:00+00:00": 66.93499755859375
    },
    "sentiment": 0.9371324181556702
  },
  {
    "title": "Incyte drops 5 clinical drug candidates following strategic review",
    "published": 1722341640,
    "day_prices": {
      "2024-07-30T13:30:00+00:00": 69.33000183105469,
      "2024-07-30T14:30:00+00:00": 66.2300033569336,
      "2024-07-30T15:30:00+00:00": 66.20999908447266,
      "2024-07-30T16:30:00+00:00": 65.63999938964844,
      "2024-07-30T17:30:00+00:00": 65.8499984741211,
      "2024-07-30T18:30:00+00:00": 66.98999786376953,
      "2024-07-30T19:30:00+00:00": 66.93499755859375
    },
    "sentiment": 0.8389382362365723
  },
  {
    "title": "Incyte Corporation (INCY) Q2 2024 Earnings Call Transcript",
    "published": 1722338947,
    "day_prices": {
      "2024-07-30T13:30:00+00:00": 69.33000183105469,
      "2024-07-30T14:30:00+00:00": 66.2300033569336,
      "2024-07-30T15:30:00+00:00": 66.20999908447266,
      "2024-07-30T16:30:00+00:00": 65.63999938964844,
      "2024-07-30T17:30:00+00:00": 65.8499984741211,
      "2024-07-30T18:30:00+00:00": 66.98999786376953,
      "2024-07-30T19:30:00+00:00": 66.93499755859375
    },
    "sentiment": 0.9265851378440857
  },
  {
    "title": "Incyte: Q2 Earnings Snapshot",
    "published": 1722338020,
    "day_prices": {
      "2024-07-30T13:30:00+00:00": 69.33000183105469,
      "2024-07-30T14:30:00+00:00": 66.2300033569336,
      "2024-07-30T15:30:00+00:00": 66.20999908447266,
      "2024-07-30T16:30:00+00:00": 65.63999938964844,
      "2024-07-30T17:30:00+00:00": 65.8499984741211,
      "2024-07-30T18:30:00+00:00": 66.98999786376953,
      "2024-07-30T19:30:00+00:00": 66.93499755859375
    },
    "sentiment": 0.5708149671554565
  },
  {
    "title": "Incyte Corporation 2024 Q2 - Results - Earnings Call Presentation",
    "published": 1722327348,
    "day_prices": {
      "2024-07-30T13:30:00+00:00": 69.33000183105469,
      "2024-07-30T14:30:00+00:00": 66.2300033569336,
      "2024-07-30T15:30:00+00:00": 66.20999908447266,
      "2024-07-30T16:30:00+00:00": 65.63999938964844,
      "2024-07-30T17:30:00+00:00": 65.8499984741211,
      "2024-07-30T18:30:00+00:00": 66.98999786376953,
      "2024-07-30T19:30:00+00:00": 66.93499755859375
    },
    "sentiment": 0.9149841070175171
  },
  {
    "title": "Incyte raises FY24 Jakafi net product revenues  to $2.71B - $2.75B",
    "published": 1722320700,
    "day_prices": {
      "2024-07-30T13:30:00+00:00": 69.33000183105469,
      "2024-07-30T14:30:00+00:00": 66.2300033569336,
      "2024-07-30T15:30:00+00:00": 66.20999908447266,
      "2024-07-30T16:30:00+00:00": 65.63999938964844,
      "2024-07-30T17:30:00+00:00": 65.8499984741211,
      "2024-07-30T18:30:00+00:00": 66.98999786376953,
      "2024-07-30T19:30:00+00:00": 66.93499755859375
    },
    "sentiment": 0.9337069392204285
  },
  {
    "title": "Incyte Non-GAAP EPS of -$1.82 misses by $2.93, revenue of $1.04B beats by $30M",
    "published": 1722320040,
    "day_prices": {
      "2024-07-30T13:30:00+00:00": 69.33000183105469,
      "2024-07-30T14:30:00+00:00": 66.2300033569336,
      "2024-07-30T15:30:00+00:00": 66.20999908447266,
      "2024-07-30T16:30:00+00:00": 65.63999938964844,
      "2024-07-30T17:30:00+00:00": 65.8499984741211,
      "2024-07-30T18:30:00+00:00": 66.98999786376953,
      "2024-07-30T19:30:00+00:00": 66.93499755859375
    },
    "sentiment": 0.5174210667610168
  },
  {
    "title": "MacroGenics gets $100M in milestone payments from Incyte for Zynyz development",
    "published": 1722312180,
    "day_prices": {
      "2024-07-30T13:30:00+00:00": 69.33000183105469,
      "2024-07-30T14:30:00+00:00": 66.2300033569336,
      "2024-07-30T15:30:00+00:00": 66.20999908447266,
      "2024-07-30T16:30:00+00:00": 65.63999938964844,
      "2024-07-30T17:30:00+00:00": 65.8499984741211,
      "2024-07-30T18:30:00+00:00": 66.98999786376953,
      "2024-07-30T19:30:00+00:00": 66.93499755859375
    },
    "sentiment": 0.8782808780670166
  },
  {
    "title": "Incyte price target lowered by $3 at Oppenheimer, here's why",
    "published": 1721977140,
    "day_prices": {
      "2024-07-26T13:30:00+00:00": 68.56999969482422,
      "2024-07-26T14:30:00+00:00": 68.7300033569336,
      "2024-07-26T15:30:00+00:00": 68.87999725341797,
      "2024-07-26T16:30:00+00:00": 68.74299621582031,
      "2024-07-26T17:30:00+00:00": 68.81999969482422,
      "2024-07-26T18:30:00+00:00": 68.94999694824219,
      "2024-07-26T19:30:00+00:00": 68.91000366210938
    },
    "sentiment": 0.8183436989784241
  },
  {
    "title": "Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?",
    "published": 1721831160,
    "day_prices": {
      "2024-07-24T13:30:00+00:00": 66.01000213623047,
      "2024-07-24T14:30:00+00:00": 65.79499816894531,
      "2024-07-24T15:30:00+00:00": 66.20999908447266,
      "2024-07-24T16:30:00+00:00": 66.51499938964844,
      "2024-07-24T17:30:00+00:00": 66.51000213623047,
      "2024-07-24T18:30:00+00:00": 66.68000030517578,
      "2024-07-24T19:30:00+00:00": 66.83999633789062
    },
    "sentiment": 0.7743964791297913
  },
  {
    "title": "Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth",
    "published": 1721743265,
    "day_prices": {
      "2024-07-23T13:30:00+00:00": 65.08000183105469,
      "2024-07-23T14:30:00+00:00": 64.94499969482422,
      "2024-07-23T15:30:00+00:00": 65.22000122070312,
      "2024-07-23T16:30:00+00:00": 65.48999786376953,
      "2024-07-23T17:30:00+00:00": 65.75,
      "2024-07-23T18:30:00+00:00": 66.08000183105469,
      "2024-07-23T19:30:00+00:00": 66.08000183105469
    },
    "sentiment": 0.8197638392448425
  },
  {
    "title": "INCY or MYGN: Which Is the Better Value Stock Right Now?",
    "published": 1721317207,
    "day_prices": {
      "2024-07-18T13:30:00+00:00": 65.4000015258789,
      "2024-07-18T14:30:00+00:00": 65.95999908447266,
      "2024-07-18T15:30:00+00:00": 66.0199966430664,
      "2024-07-18T16:30:00+00:00": 66.18000030517578,
      "2024-07-18T17:30:00+00:00": 66.23999786376953,
      "2024-07-18T18:30:00+00:00": 65.83999633789062,
      "2024-07-18T19:30:00+00:00": 65.3499984741211
    },
    "sentiment": 0.9184582233428955
  },
  {
    "title": "Company News for July 10, 2024",
    "published": 1720618140,
    "day_prices": {
      "2024-07-10T13:30:00+00:00": 60.959999084472656,
      "2024-07-10T14:30:00+00:00": 60.779998779296875,
      "2024-07-10T15:30:00+00:00": 60.619998931884766,
      "2024-07-10T16:30:00+00:00": 60.099998474121094,
      "2024-07-10T17:30:00+00:00": 60.52000045776367,
      "2024-07-10T18:30:00+00:00": 60.02000045776367,
      "2024-07-10T19:30:00+00:00": 60.36000061035156
    },
    "sentiment": 0.9260013103485107
  },
  {
    "title": "The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024",
    "published": 1720522380,
    "day_prices": {
      "2024-07-09T13:30:00+00:00": 58.33000183105469,
      "2024-07-09T14:30:00+00:00": 58.88999938964844,
      "2024-07-09T15:30:00+00:00": 59.65999984741211,
      "2024-07-09T16:30:00+00:00": 60.040000915527344,
      "2024-07-09T17:30:00+00:00": 60.790000915527344,
      "2024-07-09T18:30:00+00:00": 60.56999969482422,
      "2024-07-09T19:30:00+00:00": 60.59980010986328
    },
    "sentiment": 0.7455814480781555
  },
  {
    "title": "Incyte Reports Inducement Grants under Nasdaq Listing Rule 5635(4)",
    "published": 1720518529,
    "day_prices": {
      "2024-07-09T13:30:00+00:00": 58.33000183105469,
      "2024-07-09T14:30:00+00:00": 58.88999938964844,
      "2024-07-09T15:30:00+00:00": 59.65999984741211,
      "2024-07-09T16:30:00+00:00": 60.040000915527344,
      "2024-07-09T17:30:00+00:00": 60.790000915527344,
      "2024-07-09T18:30:00+00:00": 60.56999969482422,
      "2024-07-09T19:30:00+00:00": 60.59980010986328
    },
    "sentiment": 0.9385528564453125
  },
  {
    "title": "Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates",
    "published": 1719921840,
    "day_prices": {
      "2024-07-02T13:30:00+00:00": 59.000301361083984,
      "2024-07-02T14:30:00+00:00": 58.88999938964844,
      "2024-07-02T15:30:00+00:00": 59.42499923706055,
      "2024-07-02T16:30:00+00:00": 59.36000061035156,
      "2024-07-02T17:30:00+00:00": 59.029998779296875,
      "2024-07-02T18:30:00+00:00": 59.369998931884766,
      "2024-07-02T19:30:00+00:00": 59.209999084472656
    },
    "sentiment": 0.9332619309425354
  },
  {
    "title": "Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?",
    "published": 1724945464,
    "day_prices": {
      "2024-08-29T13:30:00+00:00": 65.80000305175781,
      "2024-08-29T14:30:00+00:00": 67.12000274658203,
      "2024-08-29T15:30:00+00:00": 66.79000091552734,
      "2024-08-29T16:30:00+00:00": 66.5199966430664,
      "2024-08-29T17:30:00+00:00": 66.5,
      "2024-08-29T18:30:00+00:00": 66.43000030517578,
      "2024-08-29T19:30:00+00:00": 66.54000091552734
    },
    "sentiment": 0.9470464587211609
  },
  {
    "title": "Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely",
    "published": 1724346835,
    "day_prices": {
      "2024-08-22T13:30:00+00:00": 64.36000061035156,
      "2024-08-22T14:30:00+00:00": 63.39500045776367,
      "2024-08-22T15:30:00+00:00": 63.849998474121094,
      "2024-08-22T16:30:00+00:00": 63.54999923706055,
      "2024-08-22T17:30:00+00:00": 62.84000015258789,
      "2024-08-22T18:30:00+00:00": 62.83000183105469,
      "2024-08-22T19:30:00+00:00": 63.2400016784668
    },
    "sentiment": 0.8990617990493774
  },
  {
    "title": "Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz\u00ae) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024",
    "published": 1724254800,
    "day_prices": {
      "2024-08-21T13:30:00+00:00": 64.41999816894531,
      "2024-08-21T14:30:00+00:00": 64.31500244140625,
      "2024-08-21T15:30:00+00:00": 64.66000366210938,
      "2024-08-21T16:30:00+00:00": 64.45999908447266,
      "2024-08-21T17:30:00+00:00": 64.3949966430664,
      "2024-08-21T18:30:00+00:00": 64.3301010131836,
      "2024-08-21T19:30:00+00:00": 64.12999725341797
    },
    "sentiment": 0.877641499042511
  },
  {
    "title": "Incyte price target raised by $4 at Citi, here's why",
    "published": 1723985820,
    "day_prices": {},
    "sentiment": 0.7584574222564697
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Cochlear Limited (OtherCHEOF)",
    "published": 1723978260,
    "day_prices": {},
    "sentiment": 0.9120863080024719
  },
  {
    "title": "Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study",
    "published": 1723797300,
    "day_prices": {
      "2024-08-16T13:30:00+00:00": 61.880001068115234,
      "2024-08-16T14:30:00+00:00": 61.645999908447266,
      "2024-08-16T15:30:00+00:00": 61.66999816894531,
      "2024-08-16T16:30:00+00:00": 61.75,
      "2024-08-16T17:30:00+00:00": 62.45000076293945,
      "2024-08-16T18:30:00+00:00": 62.34000015258789,
      "2024-08-16T19:30:00+00:00": 62.0
    },
    "sentiment": 0.9386992454528809
  },
  {
    "title": "Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi\u00ae) in Relapsed or Refractory Follicular Lymphoma",
    "published": 1723753800,
    "day_prices": {
      "2024-08-15T13:30:00+00:00": 61.790000915527344,
      "2024-08-15T14:30:00+00:00": 61.58000183105469,
      "2024-08-15T15:30:00+00:00": 61.97999954223633,
      "2024-08-15T16:30:00+00:00": 61.834999084472656,
      "2024-08-15T17:30:00+00:00": 61.45500183105469,
      "2024-08-15T18:30:00+00:00": 61.529998779296875,
      "2024-08-15T19:30:00+00:00": 61.66999816894531
    },
    "sentiment": 0.9299678802490234
  },
  {
    "title": "FDA greenlights Incyte and Syndax\u2019s GvHD drug Niktimvo",
    "published": 1723739577,
    "day_prices": {
      "2024-08-15T13:30:00+00:00": 61.790000915527344,
      "2024-08-15T14:30:00+00:00": 61.58000183105469,
      "2024-08-15T15:30:00+00:00": 61.97999954223633,
      "2024-08-15T16:30:00+00:00": 61.834999084472656,
      "2024-08-15T17:30:00+00:00": 61.45500183105469,
      "2024-08-15T18:30:00+00:00": 61.529998779296875,
      "2024-08-15T19:30:00+00:00": 61.66999816894531
    },
    "sentiment": 0.8873856067657471
  },
  {
    "title": "FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication",
    "published": 1723731080,
    "day_prices": {
      "2024-08-15T13:30:00+00:00": 61.790000915527344,
      "2024-08-15T14:30:00+00:00": 61.58000183105469,
      "2024-08-15T15:30:00+00:00": 61.97999954223633,
      "2024-08-15T16:30:00+00:00": 61.834999084472656,
      "2024-08-15T17:30:00+00:00": 61.45500183105469,
      "2024-08-15T18:30:00+00:00": 61.529998779296875,
      "2024-08-15T19:30:00+00:00": 61.66999816894531
    },
    "sentiment": 0.9018096327781677
  },
  {
    "title": "Incyte builds out its arsenal of post-transplant drugs",
    "published": 1723723680,
    "day_prices": {
      "2024-08-15T13:30:00+00:00": 61.790000915527344,
      "2024-08-15T14:30:00+00:00": 61.58000183105469,
      "2024-08-15T15:30:00+00:00": 61.97999954223633,
      "2024-08-15T16:30:00+00:00": 61.834999084472656,
      "2024-08-15T17:30:00+00:00": 61.45500183105469,
      "2024-08-15T18:30:00+00:00": 61.529998779296875,
      "2024-08-15T19:30:00+00:00": 61.66999816894531
    },
    "sentiment": 0.7546698451042175
  },
  {
    "title": "Incyte and Syndax Announce U.S. FDA Approval of Niktimvo for the Treatment of Chronic Graft-Versus-Host Disease",
    "published": 1723718775,
    "day_prices": {
      "2024-08-15T13:30:00+00:00": 61.790000915527344,
      "2024-08-15T14:30:00+00:00": 61.58000183105469,
      "2024-08-15T15:30:00+00:00": 61.97999954223633,
      "2024-08-15T16:30:00+00:00": 61.834999084472656,
      "2024-08-15T17:30:00+00:00": 61.45500183105469,
      "2024-08-15T18:30:00+00:00": 61.529998779296875,
      "2024-08-15T19:30:00+00:00": 61.66999816894531
    },
    "sentiment": 0.7114827632904053
  },
  {
    "title": "Incyte\u2019s New Drug Approval Overcast by Market Limitations and Looming Patent Expirations",
    "published": 1723702860,
    "day_prices": {
      "2024-08-15T13:30:00+00:00": 61.790000915527344,
      "2024-08-15T14:30:00+00:00": 61.58000183105469,
      "2024-08-15T15:30:00+00:00": 61.97999954223633,
      "2024-08-15T16:30:00+00:00": 61.834999084472656,
      "2024-08-15T17:30:00+00:00": 61.45500183105469,
      "2024-08-15T18:30:00+00:00": 61.529998779296875,
      "2024-08-15T19:30:00+00:00": 61.66999816894531
    },
    "sentiment": 0.9016040563583374
  },
  {
    "title": "Incyte says Tafasitamab pivotal trial meets primary endpoint",
    "published": 1723692660,
    "day_prices": {
      "2024-08-15T13:30:00+00:00": 61.790000915527344,
      "2024-08-15T14:30:00+00:00": 61.58000183105469,
      "2024-08-15T15:30:00+00:00": 61.97999954223633,
      "2024-08-15T16:30:00+00:00": 61.834999084472656,
      "2024-08-15T17:30:00+00:00": 61.45500183105469,
      "2024-08-15T18:30:00+00:00": 61.529998779296875,
      "2024-08-15T19:30:00+00:00": 61.66999816894531
    },
    "sentiment": 0.652107298374176
  },
  {
    "title": "Incyte and Syndax Announce U.S. FDA Approval of Niktimvo\u2122 (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)",
    "published": 1723671240,
    "day_prices": {
      "2024-08-14T13:30:00+00:00": 61.79999923706055,
      "2024-08-14T14:30:00+00:00": 61.36000061035156,
      "2024-08-14T15:30:00+00:00": 61.45000076293945,
      "2024-08-14T16:30:00+00:00": 61.349998474121094,
      "2024-08-14T17:30:00+00:00": 61.18000030517578,
      "2024-08-14T18:30:00+00:00": 61.16999816894531,
      "2024-08-14T19:30:00+00:00": 61.5099983215332
    },
    "sentiment": 0.811042845249176
  },
  {
    "title": "FDA approves Incyte's treatment for chronic graft-versus-host disease",
    "published": 1723650107,
    "day_prices": {
      "2024-08-14T13:30:00+00:00": 61.79999923706055,
      "2024-08-14T14:30:00+00:00": 61.36000061035156,
      "2024-08-14T15:30:00+00:00": 61.45000076293945,
      "2024-08-14T16:30:00+00:00": 61.349998474121094,
      "2024-08-14T17:30:00+00:00": 61.18000030517578,
      "2024-08-14T18:30:00+00:00": 61.16999816894531,
      "2024-08-14T19:30:00+00:00": 61.5099983215332
    },
    "sentiment": 0.7954414486885071
  },
  {
    "title": "Incyte, Syndax announce FDA approval of Niktimvo",
    "published": 1723610160,
    "day_prices": {
      "2024-08-14T13:30:00+00:00": 61.79999923706055,
      "2024-08-14T14:30:00+00:00": 61.36000061035156,
      "2024-08-14T15:30:00+00:00": 61.45000076293945,
      "2024-08-14T16:30:00+00:00": 61.349998474121094,
      "2024-08-14T17:30:00+00:00": 61.18000030517578,
      "2024-08-14T18:30:00+00:00": 61.16999816894531,
      "2024-08-14T19:30:00+00:00": 61.5099983215332
    },
    "sentiment": 0.6798778772354126
  },
  {
    "title": "Incyte CMO Stein sells 11,608 common shares",
    "published": 1723603200,
    "day_prices": {
      "2024-08-14T13:30:00+00:00": 61.79999923706055,
      "2024-08-14T14:30:00+00:00": 61.36000061035156,
      "2024-08-14T15:30:00+00:00": 61.45000076293945,
      "2024-08-14T16:30:00+00:00": 61.349998474121094,
      "2024-08-14T17:30:00+00:00": 61.18000030517578,
      "2024-08-14T18:30:00+00:00": 61.16999816894531,
      "2024-08-14T19:30:00+00:00": 61.5099983215332
    },
    "sentiment": 0.9476648569107056
  },
  {
    "title": "Incyte to Present at Upcoming Investor Conferences",
    "published": 1723550400,
    "day_prices": {
      "2024-08-13T13:30:00+00:00": 61.15999984741211,
      "2024-08-13T14:30:00+00:00": 61.41999816894531,
      "2024-08-13T15:30:00+00:00": 61.540000915527344,
      "2024-08-13T16:30:00+00:00": 61.59000015258789,
      "2024-08-13T17:30:00+00:00": 61.650001525878906,
      "2024-08-13T18:30:00+00:00": 61.84000015258789,
      "2024-08-13T19:30:00+00:00": 62.0099983215332
    },
    "sentiment": 0.9168432950973511
  },
  {
    "title": "February 2025 Options Now Available For Incyte (INCY)",
    "published": 1723111020,
    "day_prices": {
      "2024-08-08T13:30:00+00:00": 60.29999923706055,
      "2024-08-08T14:30:00+00:00": 61.560001373291016,
      "2024-08-08T15:30:00+00:00": 61.130001068115234,
      "2024-08-08T16:30:00+00:00": 61.22999954223633,
      "2024-08-08T17:30:00+00:00": 61.439998626708984,
      "2024-08-08T18:30:00+00:00": 61.36000061035156,
      "2024-08-08T19:30:00+00:00": 61.84000015258789
    },
    "sentiment": 0.9470295906066895
  },
  {
    "title": "Incyte Corporation: Revised Earnings and Cautious Hold Rating Amid Unforeseen Financial Commitment",
    "published": 1723035420,
    "day_prices": {
      "2024-08-07T13:30:00+00:00": 61.54999923706055,
      "2024-08-07T14:30:00+00:00": 61.91999816894531,
      "2024-08-07T15:30:00+00:00": 61.93000030517578,
      "2024-08-07T16:30:00+00:00": 61.68000030517578,
      "2024-08-07T17:30:00+00:00": 61.15999984741211,
      "2024-08-07T18:30:00+00:00": 60.849998474121094,
      "2024-08-07T19:30:00+00:00": 60.599998474121094
    },
    "sentiment": 0.9698530435562134
  },
  {
    "title": "MacroGenics sees cash plus milestones to support  cash runway into 2026",
    "published": 1722914640,
    "day_prices": {
      "2024-08-06T13:30:00+00:00": 61.810001373291016,
      "2024-08-06T14:30:00+00:00": 62.20000076293945,
      "2024-08-06T15:30:00+00:00": 61.70000076293945,
      "2024-08-06T16:30:00+00:00": 61.8849983215332,
      "2024-08-06T17:30:00+00:00": 61.7599983215332,
      "2024-08-06T18:30:00+00:00": 61.90999984741211,
      "2024-08-06T19:30:00+00:00": 61.65999984741211
    },
    "sentiment": 0.931731641292572
  },
  {
    "title": "Incyte Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags",
    "published": 1722507283,
    "day_prices": {
      "2024-08-01T13:30:00+00:00": 65.19999694824219,
      "2024-08-01T14:30:00+00:00": 64.52999877929688,
      "2024-08-01T15:30:00+00:00": 64.4000015258789,
      "2024-08-01T16:30:00+00:00": 64.23500061035156,
      "2024-08-01T17:30:00+00:00": 64.33999633789062,
      "2024-08-01T18:30:00+00:00": 64.52999877929688,
      "2024-08-01T19:30:00+00:00": 64.70500183105469
    },
    "sentiment": 0.6282249093055725
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Terns Pharmaceuticals (TERN) and Stryker (SYK)",
    "published": 1722480180,
    "day_prices": {
      "2024-08-01T13:30:00+00:00": 65.19999694824219,
      "2024-08-01T14:30:00+00:00": 64.52999877929688,
      "2024-08-01T15:30:00+00:00": 64.4000015258789,
      "2024-08-01T16:30:00+00:00": 64.23500061035156,
      "2024-08-01T17:30:00+00:00": 64.33999633789062,
      "2024-08-01T18:30:00+00:00": 64.52999877929688,
      "2024-08-01T19:30:00+00:00": 64.70500183105469
    },
    "sentiment": 0.9233052730560303
  },
  {
    "title": "Incyte\u2019s Strong Product Performance and Growth Trajectory Merit a Buy Rating",
    "published": 1722474480,
    "day_prices": {
      "2024-08-01T13:30:00+00:00": 65.19999694824219,
      "2024-08-01T14:30:00+00:00": 64.52999877929688,
      "2024-08-01T15:30:00+00:00": 64.4000015258789,
      "2024-08-01T16:30:00+00:00": 64.23500061035156,
      "2024-08-01T17:30:00+00:00": 64.33999633789062,
      "2024-08-01T18:30:00+00:00": 64.52999877929688,
      "2024-08-01T19:30:00+00:00": 64.70500183105469
    },
    "sentiment": 0.9353057742118835
  }
]